Pemigatinib in Chinese patients with advanced/metastatic or surgically unresectable cholangiocarcinoma including FGFR2 fusion or rearrangement: Updated data from an open-label, single-arm, multicenter phase II study (CIBI375A201 study)
单位：[1]Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China[2]West China Hosp, Chengdu, Peoples R China四川大学华西医院[3]Tianjin Canc Hosp, Tianjin, Peoples R China[4]Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou, Peoples R China中山大学附属第一医院[5]Shulan Hangzhou Hosp, Hangzhou, Peoples R China[6]HuBei Canc Hosp, Wuhan, Peoples R China[7]Peking Union Med Coll Hosp, Beijing, Peoples R China[8]Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China[9]Sichuan Canc Hosp, Chengdu, Peoples R China四川省肿瘤医院[10]HUST, TongJi Hosp, TongJi Med Coll, Wuhan, Peoples R China华中科技大学同济医学院附属同济医院[11]Guangxi Med Univ, Affiliated Hosp 1, Guangxi, Peoples R China[12]Harbin Med Univ, Canc Hosp, Harbin, Peoples R China[13]Jiangsu Prov Hosp, Nanjing, Peoples R China江苏省人民医院[14]QingDao Univ, Affiliated Hosp, Qing Dao, Peoples R China[15]Innovent Biol Inc, Beijing, Peoples R China[16]Innovent Biol Inc, Shanghai, Peoples R China
Shi Guoming,Huang Xiaoyong,Wen Tianfu,et al.Pemigatinib in Chinese patients with advanced/metastatic or surgically unresectable cholangiocarcinoma including FGFR2 fusion or rearrangement: Updated data from an open-label, single-arm, multicenter phase II study (CIBI375A201 study)[J].JOURNAL OF CLINICAL ONCOLOGY.2022,40(16):E16183-E16183.
APA：
Shi, Guoming,Huang, Xiaoyong,Wen, Tianfu,Song, Tianqiang,Kuang, Ming...&Zhou, Jian.(2022).Pemigatinib in Chinese patients with advanced/metastatic or surgically unresectable cholangiocarcinoma including FGFR2 fusion or rearrangement: Updated data from an open-label, single-arm, multicenter phase II study (CIBI375A201 study).JOURNAL OF CLINICAL ONCOLOGY,40,(16)
MLA：
Shi, Guoming,et al."Pemigatinib in Chinese patients with advanced/metastatic or surgically unresectable cholangiocarcinoma including FGFR2 fusion or rearrangement: Updated data from an open-label, single-arm, multicenter phase II study (CIBI375A201 study)".JOURNAL OF CLINICAL ONCOLOGY 40..16(2022):E16183-E16183
医学